{
  "drug_id": "D4BE4598792",
  "canonical_name": "apolipoprotein a-i human apoa-i",
  "total_pmids": 20,
  "evidence_count": {
    "benefit": 10,
    "harm": 7,
    "neutral": 0,
    "unknown": 3
  },
  "evidence_blocks": [
    {
      "pmid": "22986928",
      "title": "Characterization of a human apolipoprotein a-I construct expressed in a bacterial system.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) is the major protein component of high density lipoproteins. This protein has key functions in lipoprotein metabolism and its plasma concentration is inversely correlated w",
      "confidence": "medium"
    },
    {
      "pmid": "35120132",
      "title": "Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Transgenic overexpression of apolipoprotein A-I (apoA1) has been shown to delay atherosclerosis lesion progression and promote lesion regression in mouse models; however, apoA1 is subject to oxidation",
      "confidence": "medium"
    },
    {
      "pmid": "33861588",
      "title": "Myeloperoxidase Targets Apolipoprotein A-I for Site-Specific Tyrosine Chlorination in Atherosclerotic Lesions and Generates Dysfunctional High-Density Lipoprotein.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "We previously demonstrated that apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), is an important target for myeloperoxidase (MPO)-catalyzed tyrosine chlorina",
      "confidence": "medium"
    },
    {
      "pmid": "28069582",
      "title": "Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) is the major functional protein fraction of high-density lipoprotein. The prophylactic effect and mechanism of human apoA-I on atherosclerosis (AS) were investigated in a h",
      "confidence": "medium"
    },
    {
      "pmid": "25030535",
      "title": "Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "High-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) levels are inversely associated with adverse cardiovascular outcomes. Associations between these HDL-C-related measurements",
      "confidence": "medium"
    },
    {
      "pmid": "26363436",
      "title": "Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Mutations in human apolipoprotein A-I (apoA-I) are associated with low high-density lipoprotein (HDL) cholesterol levels and pathological conditions such as premature atherosclerosis and amyloidosis. ",
      "confidence": "medium"
    },
    {
      "pmid": "24407029",
      "title": "Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Preclinical and clinical studies have shown beneficial effects of infusions of apolipoprotein A-I (ApoA-I) on atherosclerosis. ApoA-I is also a target for myeloperoxidase-mediated oxidation, leading i",
      "confidence": "medium"
    },
    {
      "pmid": "29437574",
      "title": "CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux",
      "confidence": "medium"
    },
    {
      "pmid": "25170076",
      "title": "Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Autoantibodies to apolipoprotein A-I (anti-apoA-I IgG) have been shown to be both markers and mediators of cardiovascular disease, promoting atherogenesis and unstable atherosclerotic plaque. Previous",
      "confidence": "medium"
    },
    {
      "pmid": "38987727",
      "title": "Low HDL-C/ApoA-I index is associated with cardiometabolic risk factors and coronary artery calcium: a sub-analysis of the genetics of atherosclerotic disease (GEA) study.",
      "direction": "unknown",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The high-density lipoprotein cholesterol to apolipoprotein A-I index (HDL-C/ApoA-I) may be practical and useful in clinical practice as a marker of atherosclerosis. This study aimed to investigate the",
      "confidence": "medium"
    },
    {
      "pmid": "21811627",
      "title": "Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Amyloidoses constitute a group of diseases in which soluble proteins aggregate and deposit extracellularly in tissues. Nonhereditary apolipoprotein A-I (apoA-I) amyloid is characterized by deposits of",
      "confidence": "medium"
    },
    {
      "pmid": "33296791",
      "title": "Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits.",
      "direction": "unknown",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-II (apoAII) is the second major apolipoprotein of the high-density lipoprotein (HDL) particle, after apoAI. Unlike apoAI, the biological and physiological functions of apoAII are uncl",
      "confidence": "medium"
    },
    {
      "pmid": "37913855",
      "title": "Interactions of variants of human apolipoprotein A-I with biopolymeric model matrices. Effect of collagen and heparin.",
      "direction": "unknown",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The extracellular matrix (ECM) is a complex tridimensional scaffold that actively participates in physiological and pathological events. The objective of this study was to test whether structural prot",
      "confidence": "medium"
    },
    {
      "pmid": "39643078",
      "title": "Inhibiting IP6K1 confers atheroprotection by elevating circulating apolipoprotein A-I.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Atherosclerotic cardiovascular diseases are the leading cause of death. Apolipoprotein A-I (apoA-I) mediates cholesterol efflux to lower the risks of atherosclerosis. Elevating circulating apoA-I is a",
      "confidence": "medium"
    },
    {
      "pmid": "40371638",
      "title": "Asparagine endopeptidase cleaves apolipoprotein A1 and accelerates pathogenesis of atherosclerosis.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Atherosclerosis is a slowly progressing inflammatory disease characterized with cholesterol disorder and intimal plaques. Asparagine endopeptidase (AEP) is an endolysosomal protease that is activated ",
      "confidence": "medium"
    },
    {
      "pmid": "40263360",
      "title": "Apolipoprotein-A1 transports and regulates MMP2 in the blood.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Synthesized in the liver and intestines, apolipoprotein A1 (APOA1) transports cholesterol in high density lipoproteins from atherosclerotic lesions to the liver, protecting against atherosclerotic pla",
      "confidence": "medium"
    },
    {
      "pmid": "20425244",
      "title": "Biological properties of apolipoprotein a-I mimetic peptides.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Apolipoprotein A-I (apoA-I) mimetic peptides resemble the physiochemical properties of the helices of apoA-I and show promise for the treatment of atherosclerotic vascular diseases and other chronic i",
      "confidence": "medium"
    },
    {
      "pmid": "35304099",
      "title": "The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "Protein lysine carbamylation is an irreversible post-translational modification resulting in generation of homocitrulline (N-ε-carbamyllysine), which no longer possesses a charged ε-amino moiety. Two ",
      "confidence": "medium"
    },
    {
      "pmid": "18287885",
      "title": "Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.",
      "direction": "benefit",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "An increased plasma level of the major high-density lipoprotein (HDL) component, apolipoprotein A-I (apoA-I) is the aim of several therapeutic strategies for combating atherosclerotic disease. HDL the",
      "confidence": "medium"
    },
    {
      "pmid": "30376729",
      "title": "CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.",
      "direction": "harm",
      "model": "unknown",
      "endpoint": "unknown",
      "claim": "The risk of major adverse cardiac events (MACE) remains elevated soon after a coronary event. High-density lipoprotein (HDL) cholesterol has been proposed as a target to reduce cardiovascular endpoint",
      "confidence": "medium"
    }
  ],
  "top_pmids": [
    "22986928",
    "35120132",
    "33861588",
    "28069582",
    "25030535",
    "26363436",
    "24407029",
    "29437574",
    "25170076",
    "38987727",
    "21811627",
    "33296791",
    "37913855",
    "39643078",
    "40371638",
    "40263360",
    "20425244",
    "35304099",
    "18287885",
    "30376729"
  ]
}